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ABSTRACT
Objective: This study aims to investigate the
expression of g-synuclein in endometrioid endometrial
carcinoma and assess if the g-synuclein expression
correlates with the aggression of the tumour and its
prognostic value in endometrioid endometrial
carcinoma.
Design: This retrospective study evaluated (60)
specimens of the primary untreated endometrioid
endometrial carcinoma and (12) normal endometrium
tissues, and the expression of g-synuclein was
checked by immunohistochemistry. The correlation
between g-synuclein expression and the
clinicopathological features of patients with
endometrioid endometrial carcinoma was analysed,
and SPSS V.13.0 software was used for statistical
analysis.
Results: The expression of g-synuclein was positive in
48.3% (29/60) endometrioid endometrial carcinomas
compared with the control group, and the difference
was signiﬁcant (p¼0.001). The expression level of g-
synuclein in endometrioid endometrial carcinoma was
closely associated with FIGO (International Federation
of Gynecology and Obstetrics) stages, the depth of
myometrial invasion and lymph nodes metastases
(p<0.05), but not correlated with the histopathological
grades, the patient’s age and the expression of ER
(estrogen receptor) and PR (progesterone receptor)
(p>0.05). In univariate and multivariate analyses, the
g-synuclein expression was signiﬁcantly associated
with a shorter overall survival (95% CI 1.429 to
101.892, p¼0.020).
Conclusions: This study suggests that the expression
of g-synuclein is expected to be a useful marker for
endometrioid endometrial carcinoma invasion,
metastasis and prognosis in endometrioid endometrial
carcinoma.
INTRODUCTION
Endometrial carcinoma is one of the most
common gynaecological malignancies, and
its incidence has recently increased, in the
Western countries and in China.
1 Patients
with advanced stage endometrial carcinoma
frequently exhibits a poor prognosis, even
after radical resection combined with radio-
therapy or chemotherapy.
2 These poor
outcomes are closely associated with the
progression and metastasis of the disease.
There are two different pathogenetic types of
endometrial carcinoma. And the endome-
trioid adenocarcinoma, which is known as
the ﬁrst pathogenetic type of endometrial
cancer, is the most common tumour among
the endometrial carcinomas. Thus, a better
understanding of the molecular mechanisms
underlying the aggressive behaviour of
endometrioid endometrial carcinoma is
necessary to identify potential targets for
efﬁcient therapy.
g-Synuclein, initially identiﬁed as a breast
cancer-speciﬁc gene 1 (BCSG1),
3 maps to
chromosome region 10q23 and is composed
of ﬁve exons and transcribed into
a messenger RNA of about 1 kb, coding 127
amino acids.
4 It is a member of synucleins
family of small proteins, which is consisting
of three known members, synuclein
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- The clinical and pathological signiﬁcances of
g-synuclein expression in endometrioid endo-
metrial carcinoma.
- The relationship between the g-synuclein expres-
sion and the progression of the endometrioid
endometrial carcinoma patients.
- The prognostic value of the g-synuclein expres-
sion in the endometrioid endometrial carcinoma.
Key messages
- The expression of g-synuclein was positive in
48.3% endometrioid endometrial carcinoma; the
expression of g-synuclein was raised up with the
stage of endometrioid endometrial carcinoma;
the g-synuclein expression could predict bad
prognosis for the patients with endometrioid
endometrial carcinoma.
Strengths and limitations of this study
- The idea was creative and we have a complete
and accurate data of the patients.
- This is a preliminary data study and a bigger
number of samples are needed for our study.
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Open Access Researcha (SNCA), synuclein b (SNCB) and synuclein g
(SNCG).
5 While synucleins are highly expressed in
neuronal cells, emerging as the central player in the
fundamental neural processes and are involved with
neurodegenerative diseases.
6 a-Synuclein and b-synu-
clein are the major components in the form of patho-
logically insoluble deposits characteristic of Alzheimer’s
disease and Parkinson’s disease.
78However, g-synuclein
is not clearly involved in neurodegenerative diseases.
Instead, it has been implicated in human neoplastic
diseases.
3 Several studies have demonstrated that g-
synuclein is abnormally expressed in a high percentage
of advanced and metastatic breast and ovarian tumours
but not in normal or benign breast tissues.
9 Further-
more, g-synuclein expression was strongly correlated
with disease progression, by that g-synuclein can stimu-
late proliferation and induce invasion and metastasis of
breast cancer cells.
10 And previous studies of g-synuclein
expression in breast tissues indicated that g-synuclein
increased resistance to certain chemotherapeutic or
antimicrotubule agents.
11 12 Besides, it was found that g-
synuclein was also abnormally expressed in a high
percentage of tumour tissues of other cancer types
including liver, oesophagus, gastric, cervical, colon,
prostate, lung, pancreatic ductal adenocarcinoma cancer
patients and so on.
13 14 The clinical follow-up studies
conﬁrmed that patients with g-synuclein expression
predict poor clinical outcome in breast cancer
9 and in
colon cancer.
14 Morgan et al
15 demonstrated that g-
synuclein could be a novel biomarker as a prognostic
tool and a therapeutic target in uterine papillary serous
carcinoma. And Mhawech-Fauceglia
16 considered that
SNCG protein expression is associated with poor
outcome in endometrial adenocarcinoma. However,
Zhou et al
17 had an opposite conclusion in oesophagus
cancer, in which g-synuclein might play a role as a nega-
tive regulator in the development of human oesophagus
cancer. Therefore, further study in cancer tissues is
needed to understand the roles of g-synuclein in the
development of other human neoplastic diseases.
In this study, we examined the expression of g-synu-
clein in the 60 specimens of the endometrial carcinoma
and 12 normal endometrium. The histological subtype
of the endometrial cancer was the endometrioid
adenocarcinoma. To better understand the clinical
features relevant with the expression of g-synuclein, the
relationship between the expression of g-synuclein, ER,
PR and all clinicopathological features of the patients
were explored and analysed.
MATERIALS AND METHODS
Clinical specimen
This study was reviewed and approved by The First
Afﬁliated Hospital of Guangxi Medical University. The
medical records of 60 endometrial carcinomas and 12
normal endometrium in the First Afﬁliated Hospital of
Guangxi Medical University from 2004 to 2009 were
reviewed to have the information of clinical data and
detailed follow-up results. Parafﬁn blocks of 60 tumour
tissues and 12 normal endometrium were obtained from
the archives of the Pathology Department. The histo-
logical subtype of all the tumour tissues was endome-
trioid adenocarcinoma. The pathological review
conﬁrmed the diagnosis. Clinical stages were diagnosed
according to International Federation of the Gynecology
and Obstetrics stage system of 1988. None of the patients
had received any therapy before surgery. All the primary
tumours were treated by comprehensive staging surgery
and with speciﬁc adjuvant treatments if needed based on
FIGO 2003 and NCCN2006.
Among 60 endometrioid endometrial cancer patients,
26 (43.3%) patients were in stage I, 10 (16.7%) patients
were in stage II, 23 (38.3%) patients were in stage III
and 1 (1.7%) was in stage IV. Patients’ age ranged from
30 to 72 years (mean6SD, 51.368.8). The median
follow-up length was 45.5 months (ranged from 3 to
69.5 months after surgery). Thirty-seven endometrioid
endometrial cancer patients received pelvic lymphade-
nectomy for high-risk factors of lymph node metastasis,
according to the pathological grade by preoperative
endometrium biopsy and the depth of myometrial
invasion by image scan, and 16.2% (6/37) were found to
have lymph nodes metastasis. The detailed clinicopath-
ological characteristics of the patients were listed in
table 2.
During the follow-up, 26.7% (16/60) of patients died
of endometrioid endometrial carcinoma, in which 13.9%
(5/36) was in stage I/II and 45.8% (11/24) was in stage
III/IV. And 10.0% (6/60) patients developed recurrence
after surgery. Overall survival (OS) time was calculated
from the date of surgery to death or the last follow-up.
Disease-free survival (DFS) time was calculated for
patients from the date of surgery to the date of disease
progression (local recurrence or distant metastasis).
Immunohistochemistry
As we previously described,
9 deparafﬁnised, rehydrated
and acid-treated parafﬁn-embedded slides of endome-
trium specimens (5 mm thick) were treated with 3%
H2O2 for 10 min and blocked with 5% goat serum
albumin for 10 min. Sections were incubated with the
speciﬁc mouse monoclonal antibodies against g-synu-
clein (sc-65979; Santa Cruz Biotechnology, Santa Cruz,
California, USA) diluted 1:100 at 378C for 60 min,
followed by the incubation with the Polyer HRP (Horse
Radish Peroxidase) (mouse/rabbit) secondary anti-
bodies (IHC Kit; Maixim’s-Bio, Fuzhou, China). After
three washes of phosphate-buffered sulphate, the
staining was accomplished by using DAB Kit (Zhongshan
Goldenbridge Biotechnology, Beijing, China) according
to the manufacturers’ instructions. Sections were coun-
terstained with haematoxylin, dehydrated and mounted.
Positive cases were deﬁned by the presence of intracel-
lular staining with red/brown colour in malignant cells.
As seen in positive controls, parafﬁn sections from
breast cancer patients with conﬁrmed strong and
g-synuclein-speciﬁc staining in the previous study
9 were
used. Negative cases were deﬁned by the absence of
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body was omitted for a negative control. The cytoplasmic
staining intensity for g-synuclein and the positive case
was regarded as >20% of tumour cells with immunos-
taining.
9
Immunohistochemical expression was evaluated
under light microscopy independently by two experi-
enced pathologists without the knowledge of the
patients’ backgrounds and clinicopathological data.
Statistical analysis
Statistical analyses were performed using SPSS V.13.0
software. Pearson c
2 test and Fisher’s exact test were
used to analyse the differences of g-synuclein protein
expression between cancer and non-cancer tissues, and
the correlations between g-synuclein, ER, PR levels and
patient clinicopathological characteristics were assessed.
The KaplaneMeier method was used to estimate DFS
and OS rates, and the survival differences were analysed
by log-rank test. The Cox proportional hazard model was
used for multivariate analysis to investigate the inde-
pendence of the risk factors identiﬁed as signiﬁcant
factors after the univariate analysis. All statistical analyses
were two sided, and p<0.05 was considered statistically
signiﬁcant.
RESULTS
The expression of g-synuclein in endometrial carcinoma
As summarised in table 1, 29 of 60 (48.3%) tumour
samples displayed clear staining of g-synuclein protein
exclusively in the cytoplasm of malignant cells at
different expression levels (ﬁgure 1). While no positive
staining of g-synuclein was detected in all 12 normal
endometrium tissues (p¼0.001).
Correlation with the clinicopathological features
The correlations between g-synuclein expression and
clinicopathological characteristics of all endometrioid
endometrial carcinoma patients were analysed and
shown in table 2. As it is shown, the g-synuclein expres-
sion in stage I, stage II, stage III and stage IV were 26.9%
(7/26), 60.0% (6/10), 65.2% (15/23) and 100.0%
(1/1), respectively (p¼0.018). The difference between
stage I versus stage II and stage III versus stage IV were
not signiﬁcant, so we used the c
2 segmentation method,
and we found that the difference of g-synuclein between
stage I/II versus III/IV was signiﬁcant (p¼0.020). Simi-
larly, there was a higher percentage of g-synuclein
expression in lymph node-positive tumours compared
with the lymph node-negative tumours (6/6 (100%) vs
14/31 (45.2%), p¼0.022). And the expression of g-
synuclein was detectable in 31.7% of patients with depth
of myometrial invasion<1/2, while it raised to 84.2% in
patients with myometrial invasion $1/2 (p¼0.000). And
the expression of g-synuclein was upraised from grade 1
to grade 3 (from 40.9% to 58.3%), but the difference was
not signiﬁcant (p>0.05). However, there was no signiﬁ-
cant correlation between g-synuclein expression and
patient age and ER/PR expression (p>0.05).
Correlations of clinical outcomes of endometrioid
endometrial carcinoma patients with g-synuclein
expression
To study whether g-synuclein is a prognostic factor for
endometrioid endometrial carcinoma, we correlated g-
synuclein expression in tumours with a median follow-up
length of 45.5 months (range from 3 to 69.5 months)
after cancer surgery. g-Synuclein-positive patients
showed a signiﬁcantly poorer prognosis than those with
negative g-synuclein expression in KaplaneMeier anal-
ysis of OS (ﬁgure 2, c
2¼5.181, p¼0.023). KaplaneMeier
analysis did not reveal any signiﬁcant differences of g-
synuclein expression on DFS (data not shown). During
follow-up, 12 (41.4%) patients with g-synuclein-positive
tumour and 4 (12.9%) patients with g-synuclein-negative
tumour died of endometrioid endometrial carcinoma
(c
2¼6.213, p¼0.013).
Univariate analysis showed that several factors were
signiﬁcantly associated with poor OS (p<0.05): deep
myometrial invasion (95% CI 1.918 to 15.998, p¼0.002),
advanced stage (stage III/IV) (95% CI 1.404 to 4.694,
Table 1 The expression of g-synuclein endometrial




2 p Value Positive %
Normal* 12 0 0 0.001y
Tumourz 60 29 48.3
*Normal tissue of endometrium.
yFischer’s exact test.
zTissue of endometrial carcinoma.
Figure 1 (A) Representative
immunohistochemical staining for
g-synuclein in the cytoplasm of
human endometrial carcinoma
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The relationship between g-synuclein and endometrioid endometrial carcinomap¼0.002) and g-synuclein expression (95% CI 3.692 to
208.257, p¼0.003). When analysed with multivariate
analysis, g-synuclein expression, myometrial invasion
and clinical stage were signiﬁcant independent prog-
nostic factors for OS (table 3). No signiﬁcant differences
were found between g-synuclein expression and DFS,
either analysed with univariate analysis or multivariate
analysis (p>0.05) (data not shown).
DISCUSSION
This study used an immunohistochemical method to
detect the expression of g-synuclein in parafﬁn-
embedded tissues from Chinese’s patients with endo-
metrioid endometrial carcinomas. We presented the
clinical and experimental data to indicate that g-synu-
clein played a key role in endometrioid endometrial
carcinoma invasion and metastasis. We analysed the
relationship between g-synuclein expression in 60
endometrioid endometrial carcinoma tissues and the
clinicopathological characteristics and conﬁrmed that
endometrioid endometrial carcinoma tissues exhibited
abundant g-synuclein expression in the cytoplasm of
cancer cells, in contrast to normal endometrium tissues,
in which no g-synuclein expression was detectable.
Moreover, the frequency of g-synuclein expression was
a stage speciﬁc for endometrioid endometrial carcinoma
with the positive rate raised up from stage I to stage IV
(from 26.9% to 100%). Similar studies also demon-
strated that g-synuclein expression was stage speciﬁc in
breast, ovarian, colon cancer and many other different
cancer types.
13 18 A previous study
9 demonstrated that
the demethylation in a CpG island located in exon 1 of
g-synuclein is a primary reason for the aberrant expres-
sion of this protein in a variety of different cancer types.
The loss of epigenetic control by demethylation of
g-synuclein gene can be used as a sensitive molecular
tool in early detection in morphologically normal tissues
before tumours emerge.
13
Deep myometrial invasion and lymph nodes metastasis
are recognised as important features of malignant
tumours. A prior study
19 has been demonstrated that
expression of g-synuclein in breast cancer cells leads to
a signiﬁcant increase in motility and a profound
augmentation of metastasis. Consistent with the ability to
confer metastatic potential to breast cancer cells, studies in
colon and ovarian cancer indicated that patients with
positive g-synuclein expression had a statistically higher
incidence of metastasis compared with patients with g-
synuclein negative cancer.
14 In this study, we also found
that patients with positive g-synuclein expression in
endometrioid endometrial carcinomas had statistically
higher incidence for deep myometrial invasion and lymph
node metastasis compared with patients with negative g-
synuclein expression (p<0.05). Although the signiﬁcant
correlation was not reached, there was a tendency that g-
synuclein expression increased from grade 1 to grade 3




2 p Value Positive %
Age 0.007 0.935
<50 21 10 47.6
$50 39 19 48.7
Stage* 0.01y
I 26 7 26.9
II 10 6 60.0
III 23 15 65.2
IV 1 1 100.0
Grade 0.995 0.608
G1 22 9 40.9
G2 26 13 50.0
G3 12 7 58.3
Lymph node metastasis 0.02y
Positive 6 6 100.0
Negative 31 14 45.2
Depth of endometrial invasion 14.322 0.000
<1/2 41 13 31.7
S1/2 19 16 84.2
ER status 0.537 0.464
Negative 18 10 55.6
Positive 42 19 45.2
PR status 1.115 0.291
Negative 15 8 53.3
Positive 45 21 38.2
*The difference between stage I versus stage II and stage III versus stage IV were not signiﬁcant, so we used the c
2 segmentation method and
we found that the difference of g-synuclein between stage I/II versus III/IV was signiﬁcant (p¼0.020).
yFischer’s exact test.
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cancers, and we believe that if these results are conﬁrmed
in a larger cohort, we would have a conclusion of demo-
graphic value. All these results gave evidence that g-synu-
clein may indeed function as a key mediator of cancer cell
invasion and metastasis. This is in line with the notion that
g-synuclein promotes disease progression.
20
While, how g-synuclein induces disease progression
in different cancer types remains unclear. Since g-
synuclein gene ampliﬁcation and mutation were not
detected in breast tumours, transcriptional activation
could be responsible for its abundant expression in
malignant cancer cells.
9 Previous studies have demon-
strated that ectopic expression of g-synuclein increased
breast cancer cell growth by inhibiting the mitotic
checkpoint control through interaction with BubR1.
21
In previous in vitro studies, retinoblastoma cell lines
over-expressing g-synuclein were shown to have higher
MMP9 protein level and activity, which were enhanced
in cell motility and invasion, indicating that g-synuclein
increased invasion might be mediated through the
activation of matrix metallo proteinases (MMP)
proteins.
22 The study by Pan et al
18 in breast and ovarian
cancer indicated that the small G-protein RHO
GTPases and extracellular signal-regulated kinase
(ERK) may be involved in g-synuclein-enhanced cell
motility and metastasis. Li et al
23 revealed that g-synu-
clein induced cell proliferation and migration by
physically interacted with Insulin Like Growth Factor I
Receptor (IGF-IR) and Insulin Receptor Substrate 2
(IRS-2). It has also been shown that g-synuclein could
replace the function of heat shock protein 90, chap-
erone ER-a 36 activity, stimulate ligand-dependent cell
growth and render tamoxifen resistance.
24
Figure 2 KaplaneMeier estimation of overall survival (OS).
Table 3 Cox univariate and multivariate analyses of overall survival
Variable
Overall survival
HR (95% CI) p Value
Univariate analysis
Age
<50 vs S50 0.805 (0.292 to 2.217) 0.675
Stage
III/IV vs I/II 2.567 (1.404 to 4.694) 0.002
Grade
G3 vs G2 vs G1 1.914 (0.981 to 3.733) 0.057
Depth of endometrial invasion
>1/2 vs &1/2 5.539 (1.918 to 15.998) 0.002
Lymph node invasion
Positive versus negative 0.556 (0.261 to 1.183) 0.127
ER status
Positive versus negative 1.939 (0.552 to 6.807) 0.301
PR status
Positive versus negative 0.987 (0.315 to 3.035) 0.970
g-Synuclein
Positive versus negative 27.729 (3.692 to 208.257) 0.003
Multivariate analysis
Stage
Ⅲ/Ⅳ vs Ⅰ/Ⅱ 2.903 (1.010 to 8.340) 0.048
Depth of invasion
>1/2 vs &1/2 2.831 (1.033 to 7.757) 0.031
g-Synuclein
Positive versus negative
>1/2 vs &1/2 12.331 (1.429 to 101.892) 0.020
Multivariable analysis was performed using stepwise Cox proportional hazards regression with forward selection. Candidate exploratory
variables included clinical age, grade, stage, depth of invasion, lymph node invasion, ER status, PR status and g-synuclein.
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The relationship between g-synuclein and endometrioid endometrial carcinomaIn our study, we conﬁrmed that g-synuclein was
a predictor of OS along with stage, depth of myometrial
invasion with KaplaneMeier analysis and univariate anal-
yses, similar to some reports that g-synuclein expression is
linked to lower survival rates in different kinds of
tumours.
14 19 And multivariable analyses showed that
g-synuclein was correlated with OS of the patients, which is
the same as previous observations of an association
between g-synuclein expression and OS in uterine
papillary serous carcinoma
15 and is the same with
Mhawech-Fauceglia,
16 who considered that g-synuclein
protein expression is associated with poor outcome in
endometrial adenocarcinoma and g-synuclein expression
as an independent prognostic factor in endometrial
adenocarcinoma. Probably, due to the small number of
the patients who got a recurrence (only 6 of 60 patients
formed disease recurrence), when analysed the impact of
g-synuclein expression and clinicopathological features to
the prognosis of DFS, no signiﬁcant difference was found
(data not shown), in contrast to previous studies.
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Therefore, more specimens will be required for statistically
meaningful comparisons.
In summary, we have shown that the expression of g-
synuclein in endometrioid endometrial carcinoma tissues
was stage speciﬁc and tightly correlated with the depth of
myometrial invasion, lymph node metastasis. g-Synuclein
is likely to play an important role in the invasion and
metastasis of endometrioid endometrial carcinoma, and it
may play an important role in the prediction for prog-
nosis in endometrioid endometrial carcinoma. Additional
functional studies will be necessary to further clarify the
role that g- s y n u c l e i nm a yp l a yi nt u m o u r i g e n e s i sa n d
distant metastasis and in g-synuclein targeting biotherapy.
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